Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series: World’s leading Event Organizer
As per available reports Neuraminidase inhibitor involves 1 Conference and 5 National symposiums are presently dedicated exclusively to Neuraminidase inhibitor. about 7 Open access articles and 28 Conference Proceedings are being published on Neuraminidase Inhibitors.
Neuraminidase inhibitors are a class of drugs which block the neuraminidase enzyme. they block the function of viral neuraminidases of the influenza virus, by preventing its reproduction by budding from the host cell. Neuraminidase inhibitors act against both influenza A and influenza B. The neuraminidase inhibitors oseltamivir and zanamivir were approved in the US and Europe for treatment and prevention of influenza A and B.For flu antiviral therapeutics neuraminidase enzyme playa a mojor role.
OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.
Scope and Importance:
Neuraminidase inhibitor Conference provides the scope for opportunities to learn progressed by international scientists and academicians. Neuraminidase inhibitor Conference offers excessive quality content to suit the diverse professional development of these medicines to treat people and animals all over the globe. It is a perfect platform to discuss the current discoveries and developments in the field of Antiviral drugs.
Neuraminidase is a surface glycoprotein that has enzymatic activity essential for the replication of influenza A and B . The enzyme catalyses the cleavage of the α-ketosidic linkage that exists between a terminal sialic acid, N-acetyl neuraminic acid and an adjacent sugar residue. This action has a number of important effects that enable the spread of the virus within the respiratory tract. These effects include the release of the virus from infected cells, the prevention of viral aggregates after release from host cells, the prevention of viral inactivation and the promotion of viral penetration into respiratory cells.
Neuraminidase inhibitors were developed to capitalize on the essential role of neuraminic acid in influenza virus replication.For influenza treatment . The main drugs of current clinical value are the neuraminidase inhibitors oseltamivir (oral delivery) and zanamivir (inhaled), licensed almost universally. Intravenous zanamivir is also in phase III trials. Two other neuraminidase inhibitors, peramivir (intravenous) and laninamivir (inhaled), currently have limited licence approval (Japan and Korea, and Japan, respectively). Both are under development for wider approval.
As recommendation of IDSA, clinicians and doctors start antiviral treatment with oral oseltamivir for any hospitalized patient with suspected or confirmed influenza. In the U.S., oral oseltamivir or inhaled zanamivir (approved for treatment from age 7 years) is recommended for any outpatient suspected or confirmed to have influenza who is in a group at higher risk for complications from influenza - children younger than 2 years of age, elderly people, pregnant women, people with certain chronic conditions. When oseltamivir resistance is suspected or confirmed in a seriously ill or immunocompromised influenza patient, intravenous zanamivir is recommended and is available on a compassionate use basis from its manufacturer with FDA approval.
The respiratory antivirals market in Asia-Pacific is expected to become the growth center for the global respiratory antivirals market. The respiratory antivirals markets in Japan and India are also likely to show a significant growth during the forecast period of 2014 to 2019. The higher CAGRs of these markets can mainly be attributed to the rising patient population, increasing middle-class incomes, surge in the health insurance market, and increased awareness about quality healthcare.
International symposium and workshops
29th International Conference on Antiviral Research (ICAR), April 17-21, 2016, USA.
British Infection Association's 9th HIV Dilemmas Meeting, January 29 2016, UK.
5th Eastern Europe and Central Asia AIDS Conference, March 23-25, 2016, Russia.
List of Best International Conferences:
2nd Flu Conference
November 17-19, 2016 San Francisco, USA.
2nd Infectious Diseases Congress
August 25-27, 2016 Philadelphia, USA.
2nd Parasitology Conferences
August 01-03, 2016 Manchester, UK.
2nd Influenza Conferences
September 12-14, 2016 Berlin, Germany.
3rd Veterinary Summit
November 14-16, 2016 Atlanta, USA.
European Infectious Diseases Conference
August 1-3, 2016 Frankfurt, Germany.
Children Vaccines Congress
October 10-12, 2016 Kuala Lumpur, Malaysia.
4th Immunology Conference
October 24-26, 2016, Chicago, USA.
Relevant Society and Associations
This page will be updated regularly.
This page was last updated on 11th Sep, 2015
1-702-508-5200 Ext:8031, 8041
1-702-508-5200 Ext:8045, 8047
Immunology & Microbiology Conferences
Nursing and Healthcare Conferences
Clinical and Biochemistry Conferences
1-702-508-5200 Ext:8031, 8037
Material Science Conferences
Genetics & Mol Biology Conferences
Media Partners | Advertising